{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:02:48Z","timestamp":1794528168015,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":39,"publisher":"Springer New York","isbn-type":[{"value":"9781493940097","type":"print"},{"value":"9781493940110","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-4011-0_12","type":"book-chapter","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:40:51Z","timestamp":1472604051000},"page":"139-148","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative Proteomics Analysis of Leukemia Cells"],"prefix":"10.1007","author":[{"given":"Sebastian","family":"Halbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Dengjel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","volume":"131","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999) Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131:207\u2013219","journal-title":"Ann Intern Med"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5:33\u201344","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1478-811X-7-22","volume":"7","author":"FU Wohrle","year":"2009","unstructured":"Wohrle FU, Daly RJ, Brummer T (2009) Function, regulation and pathological roles of the Gab\/DOS docking proteins. Cell Commun Signal 7:22","journal-title":"Cell Commun Signal"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690\u2013698","journal-title":"Blood"},{"issue":"Suppl 3","key":"12_CR5","first-page":"428","volume":"11","author":"J Wilson-Rawls","year":"1997","unstructured":"Wilson-Rawls J, Liu J, Laneuville P, Arlinghaus RB (1997) P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2. Leukemia 11(Suppl 3):428\u2013431","journal-title":"Leukemia"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1478-811X-11-30","volume":"11","author":"S Halbach","year":"2013","unstructured":"Halbach S, Rigbolt KT, Wohrle FU, Diedrich B, Gretzmeier C, Brummer T, Dengjel J (2013) Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells. Cell Commun Signal 11:30","journal-title":"Cell Commun Signal"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/leu.2012.222","volume":"27","author":"FU Wohrle","year":"2013","unstructured":"Wohrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, La\u00dfmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T (2013) Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 27:118\u2013129","journal-title":"Leukemia"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/leu.2012.243","volume":"27","author":"C Preisinger","year":"2013","unstructured":"Preisinger C, Schwarz JP, Bleijerveld OB, Corradini E, Muller PJ, Anderson KI, Kolch W, Scholten A, Heck AJ (2013) Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells. Leukemia 27:743\u2013746","journal-title":"Leukemia"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808\u20134817","journal-title":"Blood"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm1009-1158","volume":"15","author":"CL Sawyers","year":"2009","unstructured":"Sawyers CL (2009) Shifting paradigms: the seeds of oncogene addiction. Nat Med 15:1158\u20131161","journal-title":"Nat Med"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1172\/JCI31691","volume":"117","author":"T Hunter","year":"2007","unstructured":"Hunter T (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest 117:2036\u20132043","journal-title":"J Clin Invest"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drup.2007.06.001","volume":"10","author":"A Burchert","year":"2007","unstructured":"Burchert A (2007) Roots of imatinib resistance: a question of self-renewal? Drug Resist Updat 10:152\u2013161","journal-title":"Drug Resist Updat"},{"key":"12_CR13","first-page":"114","volume":"107","author":"N Bubnoff von","year":"2010","unstructured":"von Bubnoff N, Duyster J (2010) Chronic myelogenous leukemia: treatment and monitoring. Dtsch Arztebl Int 107:114\u2013121","journal-title":"Dtsch Arztebl Int"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2018Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor BM, So C, Letvak L, Larson RA, IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2018Hare","year":"2007","unstructured":"O\u2018Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132249","journal-title":"Blood"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.17.6.865","volume":"17","author":"T O\u2018Hare","year":"2008","unstructured":"O\u2018Hare T, Eide CA, Deininger MW (2008) New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 17:865\u2013878","journal-title":"Expert Opin Investig Drugs"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345\u2013356","journal-title":"Nat Rev Cancer"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","volume":"17","author":"T O\u2018Hare","year":"2011","unstructured":"O\u2018Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17:212\u2013221","journal-title":"Clin Cancer Res"},{"key":"12_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25:7\u201322","journal-title":"Leukemia"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1074\/mcp.M112.025478","volume":"12","author":"A Sprenger","year":"2013","unstructured":"Sprenger A, Weber S, Zarai M, Engelke R, Nascimento JM, Gretzmeier C, Hilpert M, Boerries M, Has C, Busch H, Bruckner-Tuderman L, Dengjel J (2013) Consistency of the proteome in primary human keratinocytes with respect to gender, age, and skin localization. Mol Cell Proteomics 12:2509\u20132521","journal-title":"Mol Cell Proteomics"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nbt1301","volume":"25","author":"J Dengjel","year":"2007","unstructured":"Dengjel J, Akimov V, Olsen JV, Bunkenborg J, Mann M, Blagoev B, Andersen JS (2007) Quantitative proteomic assessment of very early cellular signaling events. Nat Biotechnol 25:566\u2013568","journal-title":"Nat Biotechnol"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2014.185","volume":"134","author":"V Kuttner","year":"2014","unstructured":"Kuttner V, Mack C, Gretzmeier C, Bruckner-Tuderman L, Dengjel J (2014) Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity. J Invest Dermatol 134:2381\u20132389","journal-title":"J Invest Dermatol"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1074\/mcp.M200025-MCP200","volume":"1","author":"SE Ong","year":"2002","unstructured":"Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1:376\u2013386","journal-title":"Mol Cell Proteomics"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.1021\/ac0348625","volume":"75","author":"JL Hsu","year":"2003","unstructured":"Hsu JL, Huang SY, Chow NH, Chen SH (2003) Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem 75:6843\u20136852","journal-title":"Anal Chem"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4161\/auto.6.8.12786","volume":"6","author":"AC Zimmermann","year":"2010","unstructured":"Zimmermann AC, Zarei M, Eiselein S, Dengjel J (2010) Quantitative proteomics for the analysis of spatio-temporal protein dynamics during autophagy. Autophagy 6:1009\u20131016","journal-title":"Autophagy"},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-60761-780-8_16","volume":"658","author":"J Dengjel","year":"2010","unstructured":"Dengjel J, Kratchmarova I, Blagoev B (2010) Mapping protein-protein interactions by quantitative proteomics. Methods Mol Biol 658:267\u2013278","journal-title":"Methods Mol Biol"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1074\/mcp.M800184-MCP200","volume":"7","author":"AR Kristensen","year":"2008","unstructured":"Kristensen AR, Schandorff S, Hoyer-Hansen M, Nielsen MO, Jaattela M, Dengjel J, Andersen JS (2008) Ordered organelle degradation during starvation-induced autophagy. Mol Cell Proteomics 7:2419\u20132428","journal-title":"Mol Cell Proteomics"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cell.2008.05.033","volume":"134","author":"M Kruger","year":"2008","unstructured":"Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, F\u00e4ssler R, Mann M (2008) SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134:353\u2013364","journal-title":"Cell"},{"key":"12_CR29","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1074\/mcp.M110.000323","volume":"9","author":"MD Sury","year":"2010","unstructured":"Sury MD, Chen JX, Selbach M (2010) The SILAC fly allows for accurate protein quantification in vivo. Mol Cell Proteomics 9:2173\u20132183","journal-title":"Mol Cell Proteomics"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ymeth.2006.08.001","volume":"40","author":"B Blagoev","year":"2006","unstructured":"Blagoev B, Mann M (2006) Quantitative proteomics to study mitogen-activated protein kinases. Methods 40:243\u2013250","journal-title":"Methods"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ab.2011.01.011","volume":"412","author":"C Lossner","year":"2011","unstructured":"Lossner C, Warnken U, Pscherer A, Schnolzer M (2011) Preventing arginine-to-proline conversion in a cell-line-independent manner during cell cultivation under stable isotope labeling by amino acids in cell culture (SILAC) conditions. Anal Biochem 412:123\u2013125","journal-title":"Anal Biochem"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/nprot.2006.468","volume":"1","author":"A Shevchenko","year":"2006","unstructured":"Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2006) In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1:2856\u20132860","journal-title":"Nat Protoc"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/nprot.2007.261","volume":"2","author":"J Rappsilber","year":"2007","unstructured":"Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2:1896\u20131906","journal-title":"Nat Protoc"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367\u20131372","journal-title":"Nat Biotechnol"},{"issue":"Suppl 16","key":"12_CR35","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/1471-2105-13-S16-S12","volume":"13","author":"J Cox","year":"2012","unstructured":"Cox J, Mann M (2012) 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics 13(Suppl 16):S12","journal-title":"BMC Bioinformatics"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","volume":"45","author":"CB Lozzio","year":"1975","unstructured":"Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45:321\u2013334","journal-title":"Blood"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ijc.2910180405","volume":"18","author":"E Klein","year":"1976","unstructured":"Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F (1976) Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 18:421\u2013431","journal-title":"Int J Cancer"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijc.2910230202","volume":"23","author":"LC Andersson","year":"1979","unstructured":"Andersson LC, Nilsson K, Gahmberg CG (1979) K562--a human erythroleukemic cell line. Int J Cancer 23:143\u2013147","journal-title":"Int J Cancer"},{"key":"12_CR39","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/ac050232m","volume":"77","author":"A Schlosser","year":"2005","unstructured":"Schlosser A, Vanselow JT, Kramer A (2005) Mapping of phosphorylation sites by a multi-protease approach with specific phosphopeptide enrichment and NanoLC-MS\/MS analysis. Anal Chem 77:5243\u20135250","journal-title":"Anal Chem"}],"container-title":["Methods in Molecular Biology","Chronic Myeloid Leukemia"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-4011-0_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:21:34Z","timestamp":1601040094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-4011-0_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493940097","9781493940110"],"references-count":39,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-4011-0_12","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-4011-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}